Renexxion advances former Aryx GI drug under new FDA guidance
A drug for gastrointestinal troubles shelved during Aryx Therapeutics Inc.'s 2011 demise is back in action at Renexxion LLC propelled by new FDA guidance setting aside the requirement for pre-approval cardiovascular safety outcome studies, the costly prospect of which scuttled the program's advancement at Aryx.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST